Ind-Swift Laboratories Ltd.

124.60 +0.25 ▲0.2%

26 April 2024, 02:27:50 PM
Volume: 573,561

Company Profile

Sector Healthcare Sector Icon Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Industry Icon Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.indswiftlabs.com
Market Cap 749.52 Cr.
Enterprise Value(EV) 1,539.39 Cr. 2023-09
Financial Indicators
Earnings per share (EPS) 7.49 Trailing Twelve Months Ending 2023-12
Price-Earning Ratio (PE) 16.94 Trailing Twelve Months Ending 2023-12
Industry PE 41.74 Trailing Twelve Months Ending 2023-12
Book Value / Share 95.74 Trailing Twelve Months Ending 2023-12
Price to Book Value 1.32 Calculated using Price: 126.85
Dividend Yield 0.00 Period Ending 2023-03
No. of Shares Subscribed 5.91 Cr. 59,086,860 Shares
FaceValue 10
About Ind-Swift Laboratories Ltd.
Ind-Swift Laboratories is a part of the Ind-swift Group and is based at Chandigarh, India. It has been promoted by Ind-Swift Limited in a joint venture with the Punjab State Industrial Development Corporation Limited (PSIDC). The group has established a strong reputation as innovators in the Indian pharmaceutical industry.

Ind-Swift Laboratories Ltd. Delivery

Delivered Qty
Traded Qty

Ind-Swift Laboratories Ltd. Performance

1 Day
+0.20%
1 Week
+6.91%
1 Month
+23.55%
3 Month
+19.46%
6 Month
+46.93%
1 Year
+91.69%
2 Year
+82.97%
5 Year
+234.95%
10 Year
+225.33%

Ind-Swift Laboratories Ltd. Fundamental Ratios

9 years 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03 2022-03 2023-03
Return on Equity (%) -36.36 -23.11 -15.89 7.89 8.99 -5.56 -0.78 -0.54 10.61
Return on Capital Employed (%) -1.52 1.4 2.19 4.59 9.25 5.97 8.31 7.88 13.25
Return on Assets (%) -5.22 -2.65 -1.86 1.11 1.53 -1.17 -0.18 -0.12 2.7

Ind-Swift Laboratories Ltd. Balance Sheet

Particulars 10 years 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr. 2023-09* Rs. Cr.
Shh. Funds 595 517 531 553 588 641 604 601 682 730
Non Curr. Liab. 811 717 495 438 901 828 840 814 741 726
Curr. Liab. 833 951 1,005 936 356 323 315 334 371 322
Minority Int. 0 0
Equity & Liab. 2,239 2,185 2,031 1,927 1,845 1,792 1,758 1,749 1,794 1,778
Non Curr. Assets 1,319 1,264 1,202 1,088 1,009 929 814 674 630 613
Curr. Assets 920 922 829 839 836 863 942 1,073 1,163 1,165
Misc. Exp. not W/O
Total Assets 2,239 2,185 2,031 1,927 1,845 1,792 1,758 1,749 1,794 1,778

Ind-Swift Laboratories Ltd. Profit and Loss

Particulars 10 years 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr. 2023-12 Rs. Cr. TTM
Net Sales 660 653 697 763 757 780 891 1,039 1,207 1,192
Other Income 22 16 23 26 37 33 23 44 34 30
Total Income 683 669 720 788 794 813 914 1,082 1,241 1,222
Total Expenditure -572 -546 -591 -628 -630 -636 -709 -843 -978 -949
PBIDT 111 123 129 160 163 177 206 239 263 273
Interest -117 -106 -90 -35 -92 -107 -100 -96 -92 -84
Depreciation -84 -85 -88 -87 -104 -90 -87 -131 -57 -50
Taxation 24 24 16 -14 -21 -1 -21 -15 -39 -67
Exceptional Items -53 -15 -5 -2 83 -27 -27
PAT -119 -59 -39 22 29 -21 -3 -2 48 45
Minority Interest
Share Associate 0 -1
Other Related Items
Consolidated Net Profit -119 -59 -39 22 29 -21 -3 -2 48 44
Adjusted EPS -29 -14 -9 5 6 -4 -1 0 8 7

Ind-Swift Laboratories Ltd. Cash Flow

Particulars 10 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr.
Cash Fr. Operatn. 66 98 79 96 73 -64 125 135 150 195
Cash Fr. Inv. -27 -36 -30 -31 -17 -12 -9 -10 5 -13
Cash Fr. Finan. -38 -64 -48 -69 -62 100 -133 -124 -141 -186
Net Change 0 -1 2 -4 -6 23 -17 1 14 -4
Cash & Cash Eqvt 21 20 22 16 9 30 11 12 26 17

Ind-Swift Laboratories Ltd. Shareholding Pattern

9 Qtrs 2022-03 (%) 2022-06 (%) 2022-09 (%) 2022-12 (%) 2023-03 (%) 2023-06 (%) 2023-09 (%) 2023-12 (%) 2024-03 (%)
Promoter 42.00 42.00 42.00 42.00 42.00 42.00 42.00 42.00 42.00
Public 58.00 58.00 58.00 58.00 58.00 58.00 58.00 58.00 58.00
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 86.81 86.84 86.84 86.84 86.84 86.84 86.84 86.84 48.57
No. of Shareholders (in Lacs)

Ind-Swift Laboratories Ltd. Announcements

Mon, 22 Apr 2024
Incorporation-XBRL
IND-SWIFT LABORATORIES LIMITED has informed the Exchange regarding Incorporation
Fri, 19 Apr 2024
Acquisition
Ind-Swift Laboratories Limited has informed the Exchange about the Incorporation of a wholly owned subsidiary in Dubai, UAE.
Mon, 15 Apr 2024
Updates
Ind-Swift Laboratories Limited has informed the Exchange regarding 'Statement of Debt Securities/NCD for the period ended March 31, 2024'.

Ind-Swift Laboratories Ltd. Technical Scans

Thu, 25 Apr 2024
Opening at Low Opening at Low
Making Higher Highs for 3 days Making Higher Highs for 3 days
Close Within 52 Week High Zone Close Within 52 Week High Zone
Making Higher Highs for 2 Days Making Higher Highs for 2 Days
High Increase in 1 Month High Increase in 1 Month

Ind-Swift Laboratories Ltd. Related Stocks

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 364,830.88 1,504.60 -1.0%
Cipla Ltd. 113,471.29 1,409.80 +0.3%
Dr. Reddy's Laboratories Ltd. 103,713.42 6,279.45 +1.0%
Divi's Laboratories Ltd. 101,959.84 4,003.65 +4.2%
Zydus Lifesciences Ltd. 95,944.41 949.35 -0.2%
Mankind Pharma Ltd. 95,926.91 2,391.20 -0.3%
Apollo Hospitals Enterprise Ltd. 91,425.47 6,273.50 -1.7%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-12 40.96 1,504.60 -1.0%
Cipla Ltd. Consolidated 2023-12 30.60 1,409.80 +0.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-12 19.84 6,279.45 +1.0%
Divi's Laboratories Ltd. Consolidated 2023-12 73.73 4,003.65 +4.2%
Zydus Lifesciences Ltd. Consolidated 2023-12 32.26 949.35 -0.2%
Mankind Pharma Ltd. Consolidated 2023-12 55.54 2,391.20 -0.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-12 115.83 6,273.50 -1.7%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-12 5.85 1,504.60 -1.0%
Cipla Ltd. Consolidated 2023-12 4.38 1,409.80 +0.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-12 3.86 6,279.45 +1.0%
Divi's Laboratories Ltd. Consolidated 2023-12 7.82 4,003.65 +4.2%
Zydus Lifesciences Ltd. Consolidated 2023-12 5.09 949.35 -0.2%
Mankind Pharma Ltd. Consolidated 2023-12 10.80 2,391.20 -0.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-12 13.54 6,273.50 -1.7%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 0.11 1,504.60 -1.0%
Cipla Ltd. Consolidated 2023-03 0.02 1,409.80 +0.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 0.06 6,279.45 +1.0%
Divi's Laboratories Ltd. Consolidated 2023-03 0.00 4,003.65 +4.2%
Zydus Lifesciences Ltd. Consolidated 2023-03 0.07 949.35 -0.2%
Mankind Pharma Ltd. Consolidated 2023-03 0.02 2,391.20 -0.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 0.44 6,273.50 -1.7%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 16.46 1,504.60 -1.0%
Cipla Ltd. Consolidated 2023-03 12.85 1,409.80 +0.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 21.36 6,279.45 +1.0%
Divi's Laboratories Ltd. Consolidated 2023-03 14.89 4,003.65 +4.2%
Zydus Lifesciences Ltd. Consolidated 2023-03 11.60 949.35 -0.2%
Mankind Pharma Ltd. Consolidated 2023-03 19.27 2,391.20 -0.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 15.16 6,273.50 -1.7%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 16.46 1,504.60 -1.0%
Cipla Ltd. Consolidated 2023-03 12.85 1,409.80 +0.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 21.36 6,279.45 +1.0%
Divi's Laboratories Ltd. Consolidated 2023-03 14.89 4,003.65 +4.2%
Zydus Lifesciences Ltd. Consolidated 2023-03 11.60 949.35 -0.2%
Mankind Pharma Ltd. Consolidated 2023-03 19.27 2,391.20 -0.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 15.16 6,273.50 -1.7%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 43,885.68 1,504.60 -1.0%
Cipla Ltd. Consolidated 2023-03 22,753.12 1,409.80 +0.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 24,669.70 6,279.45 +1.0%
Divi's Laboratories Ltd. Consolidated 2023-03 7,767.51 4,003.65 +4.2%
Zydus Lifesciences Ltd. Consolidated 2023-03 17,237.40 949.35 -0.2%
Mankind Pharma Ltd. Consolidated 2023-03 8,749.43 2,391.20 -0.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 16,612.50 6,273.50 -1.7%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 8,560.84 1,504.60 -1.0%
Cipla Ltd. Consolidated 2023-03 2,835.49 1,409.80 +0.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 4,507.30 6,279.45 +1.0%
Divi's Laboratories Ltd. Consolidated 2023-03 1,823.38 4,003.65 +4.2%
Zydus Lifesciences Ltd. Consolidated 2023-03 2,001.90 949.35 -0.2%
Mankind Pharma Ltd. Consolidated 2023-03 1,309.68 2,391.20 -0.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 887.50 6,273.50 -1.7%

Ind-Swift Laboratories Ltd. FAQ's

What is Ind-Swift Lab. share price?

Can I buy Ind-Swift Lab. shares now?

What is the Market Cap of Ind-Swift Lab.?

What are the key metrics to analyse Ind-Swift Lab.?

What is the 52 Week High and Low of Ind-Swift Lab.?

What is the trend of Ind-Swift Lab. share price?